1. Current Status, Position
Mr Mellstedt is Professor of Oncologic Biotherapy at the Karolinska Institute, CancerCentre Karolinska at the Karolinska University Hospital Solna, Stockholm.
2. Education
- 1996-1999: MD, PhD at the Karolinska Institute, Professor of Experimental Oncology at Uppsala University and Academic Hospital.
- Since 1999: Professor of Oncologic Biotherapy at Karolinska Insitute.
- Board certified in Internal Medicine, Hematology and Oncology.
- 2004-2009: ESMO President.
3. Research Area
- Immune biology of B-lymphoproliferative diseases and gastrointestinal cancer.
- Development of monoclonal antibody therapy and cancer vaccine in malignant B-cell disorders, colorectal and pancreatic carcinoma.
- Development of therapeutic monoclonal antibodies and thyrosine kinase receptors against the RTK ROR.
- He has published more than 500 scientific articles within these areas and written numerous chapters in text books.
Conflict of interest: Håkan Mellstedt has received honoraria from Abbvie, Amgen, Bio-Sweden, Boeringer-Ingelheim, Hospira, Roche and research grants from Merck GmBH.
Håkan Mellstedt has served on ad hoc SAB for Abbvie, Amgen, Boeringer-Ingelheim, Hospira.
Håkan Mellstedt has served on ad hoc SAB for Abbvie, Amgen, Boeringer-Ingelheim, Hospira.
